Tirzepatide has emerged as a groundbreaking therapy for type 2 diabetes, offering promising results. However, the cost of this innovative drug and its access have become key issues for patients and healthcare practitioners. While tirzepatide has been cleared by regulatory agencies, its costly nature presents a significant challenge to many. Negoti